QuidelOrtho Corp

QuidelOrtho Corp. operates as a vitro diagnostics company. It is focused on developing and manufacturing diagnostic products. The company was founded on May 27, 2022 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

QuidelOrtho Corp reports strong Q4 earnings, eyes growth opportunities

QuidelOrtho's Q4 performance reflects robust revenue growth and margin stability, driven by key diagnostic segments.
While facing challenges in certain units and regions, the company is focused on resolving supply chain issues and maintaining market leadership.
With a positive outlook for 2023, driven by new product launches and market expansion, QuidelOrtho aims for sustained growth and profitability.

QuidelOrtho Corp (QDEL) reports strong Q1 earnings, eyes global expansion

QuidelOrtho's Q1 2023 performance was strong, driven by non-respiratory revenue growth and exceeding expectations in Point-of-Care business. The company is confident in its growth drivers and ability to launch Savanna ahead of the next respiratory season. Challenges include revenue declines in certain segments and margin impacts.

QuidelOrtho Corp reports strong Q2 earnings and eyes growth opportunities

QuidelOrtho Corp's Q2 performance was robust, with strong revenue, growth in key segments, and increased cost synergies. While facing challenges in certain business areas, the company is optimistic about opportunities for growth, especially in the Point-of-Care and molecular diagnostics markets.

QuidelOrtho Corp reports strong Q3 earnings and eyes China growth

QuidelOrtho Corp's Q3 2023 earnings call highlighted strong financial performance, diversified revenue streams, and a focus on innovation and growth strategies.
The company's emphasis on respiratory products, cost efficiencies, and market expansion in China and the U.S. positions it for continued success and value creation.
Challenges include managing working capital, navigating pricing dynamics, and sustaining growth post-COVID-19, while opportunities lie in product innovation, market expansion, and strategic capital deployment.
Overall, QuidelOrtho Corp's performance reflects resilience, adaptability, and a strategic approach to driving growth and profitability in the healthcare diagnostics sector.

QuidelOrtho Corp reports 2023 earnings, eyes growth opportunities in 2024

QuidelOrtho Corp navigated challenges in 2023 due to lower respiratory season but remains focused on growth and efficiency.
Strategic initiatives include transitioning out of donor screening, investing in immuno hematology, and cost reduction measures.
Confidence in achieving financial goals by 2025, with a strong focus on business efficiency and revenue expansion opportunities.
2024 revenue guidance reflects a strategic shift towards nonrespiratory revenue growth and cost reduction for improved performance.

QuidelOrtho Corp reports revenue growth and cost savings in Q1

QuidelOrtho's Q1 2024 performance showed revenue growth and cost-saving initiatives, despite a significant goodwill impairment charge.
The company's strengths lie in strong revenue growth in key regions, diverse product portfolio, and strategic cost reductions.
Challenges include suspended guidance, lack of flu numbers update, and ongoing head count reductions, while opportunities exist in customer agreements and new product trials.

QuidelOrtho Corp reports solid Q2 results, eyes margin expansion

QuidelOrtho Corp (QDEL) is on track with revenue and EBITDA targets, focusing on margin expansion.
While facing challenges in certain revenue segments, the company is driving cost efficiencies and new product launches.
Opportunities lie in healthcare segment growth and achieving targeted margin expansion in the coming years.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its second quarter 2024 ended June 30, 2024, after the market close on Wednesday, July 31, 2024. Following the release of financial results, QuidelOrtho will hold a conference call beginning at.

QuidelOrtho to Report Second Quarter 2024 Financial Results

LOS ANGELES, CA / ACCESSWIRE / June 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.

The Schall Law Firm Encourages Investors Who Have Suffered Losses In QuidelOrtho Corporation To Make Contact

Investors can contact the law firm at no cost to learn more about recovering their losses

QuidelOrtho Corporation Investors Notice: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

LOS ANGELES--(BUSINESS WIRE)--DEADLINE TODAY: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm.

DEADLINE TODAY: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NASDAQ: QDEL) and reminds investors of the June 11, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of QuidelOrtho

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 11, 2024 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NASDAQ: QDEL) common stock between February 18, 2022 and April 1, 2024, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. On February 13, 2024, QuidelOrtho released its fou.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against QuidelOrtho Corporation (QDEL)

LOS ANGELES--(BUSINESS WIRE)--DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm.

DEADLINE TOMORROW: The Schall Law Firm Encourages Investors in QuidelOrtho Corporation with Losses to Contact the Firm

NEW YORK , June 10, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ: QDEL). Shareholders who purchased shares of QDEL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of QuidelOrtho Corporation f/k/a Quidel Corporation(QDEL) Shareholders

NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against QuidelOrtho (“QuidelOrtho” or “the Company”) (NASDAQ: QDEL) and certain of its officers.

QDEL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that QuidelOrtho Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, NY / ACCESSWIRE / June 9, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") (NASDAQ:QDEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against QuidelOrtho Corporation - QDEL

LOS ANGELES, CA / ACCESSWIRE / June 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.

The Schall Law Firm Urges Investors Who Have Experienced Losses In QuidelOrtho Corporation To Get In Touch

NEW YORK, June 08, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of QuidelOrtho Corporation (NASDAQ: QDEL) between February 18, 2022 and April 1, 2024, both dates inclusive (the “Class Period”) of the important June 11, 2024 lead plaintiff deadline.

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important June 11 Deadline in Securities Class Action – QDEL

LOS ANGELES, CA / ACCESSWIRE / June 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.

The Schall Law Firm Encourages Investors Who Have Suffered Losses in QuidelOrtho Corporation to Make Contact

NEW YORK, June 07, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in QuidelOrtho Corporation f/k/a Quidel Corporation ("QuidelOrtho" or the "Company") (NASDAQ: QDEL) of a class action securities lawsuit.

Levi & Korsinsky Reminds QuidelOrtho Corporation f/k/a Quidel Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of June 11, 2024 – QDEL

QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock?

Why Is QuidelOrtho (QDEL) Down 2.4% Since Last Earnings Report?

NEW YORK , June 7, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") (NASDAQ: QDEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against QuidelOrtho Corporation - QDEL

BENSALEM, Pa. , June 6, 2024 /PRNewswire/ -- Law Offices of Howard G.

QDEL Investors Have Opportunity to Lead QuidelOrtho Corporation Securities Fraud Lawsuit

NEW YORK, June 06, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ: QDEL).

Class Action Filed Against QuidelOrtho Corporation f/k/a Quidel Corporation (QDEL) Seeking Recovery for Investors – Contact The Gross Law Firm

LOS ANGELES, CA / ACCESSWIRE / June 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against QuidelOrtho Corporation ("QuidelOrtho" or "the Company") (NASDAQ:QDEL) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 18, 2022 and April 1, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before June 11, 2024.

The Schall Law Firm Urges Investors With Losses In QuidelOrtho Corporation To Reach Out

NEW YORK , June 6, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") (NASDAQ: QDEL) and reminds investors of the June 11, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In QuidelOrtho To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $100,000 investing in QuidelOrtho stock or options between February 18, 2022 and April 1, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of QuidelOrtho

NEW YORK , June 6, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in QuidelOrtho Corporation f/k/a Quidel Corporation ("QuidelOrtho" or the "Company") (NASDAQ: QDEL) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of QuidelOrtho investors who were adversely affected by alleged securities fraud between February 18, 2022 and April 1, 2024.

QDEL LAWSUIT ALERT: Levi & Korsinsky Notifies QuidelOrtho Corporation f/k/a Quidel Corporation Investors of a Class Action Lawsuit and Upcoming Deadline

NEW YORK , June 5, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of QuidelOrtho Corporation (NASDAQ: QDEL) between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class Period") of the important June 11, 2024 lead plaintiff deadline. SO WHAT: If you purchased QuidelOrtho common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A TOP RANKED LAW FIRM, Encourages QuidelOrtho Corporation Investors to Secure Counsel Before Important June 11 Deadline in Securities Class Action - QDEL

SAN FRANCISCO, CA / ACCESSWIRE / June 5, 2024 / Hagens Berman urges QuidelOrtho Corporation (NASDAQ:QDEL) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 18, 2022 - Apr. 1, 2024 Lead Plaintiff Deadline: June 11, 2024 Visit: www.hbsslaw.com/investor-fraud/QDEL Contact the Firm Now: QDEL@hbsslaw.com 844-916-0895 QuidelOrtho Corporation (NASDAQ: QDEL) Securities Class Action: The litigation is focused on the propriety of QuidelOrtho's past assurances about its preparedness to maintain a stable high margin revenue stream from its respiratory business in the face of the COVID-19 pandemic becoming an endemic and about its FDA submission for its purported "next flagship product" (the "Savanna RVP4 Test") being "on track.

QuidelOrtho (QDEL) Investors Who Suffered Substantial Losses After QDEL Reported Disastrous Q4 2023 Results, Terminated CEO, & Withdrew FDA Submission Should Contact Hagens Berman Before June 11, 2024 Deadline

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NASDAQ: QDEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against QuidelOrtho Corporation – QDEL

NEW YORK , June 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of QuidelOrtho Corporation f/k/a Quidel Corporation (NASDAQ: QDEL). Shareholders who purchased shares of QDEL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

News for QuidelOrtho Corp Stock (QDEL)